LY-2456302
- Generic Name
- LY-2456302
- Drug Type
- Small Molecule
- Chemical Formula
- C26H27FN2O2
- CAS Number
- 1174130-61-0
- Unique Ingredient Identifier
- DE4G8X55F5
- Background
Ly2456302 has been used in trials studying the health services research and basic science of Anxiety Disorders and Alcohol Dependence.
A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and Pleasure
- Conditions
- Depressive Disorder, MajorAnhedonia
- Interventions
- Other: Placebo
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 660
- Registration Number
- NCT06635135
- Locations
- 🇧🇪
Vitaz, Sint Niklaas, Belgium
🇧🇷CAEP Centro Avancado De Estudos E Pesquisas, Campinas, Brazil
🇧🇷Centro Integrado Facili, Sao Bernardo do Campo, Brazil
A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant
- Conditions
- AnhedoniaDepressive Disorder, Major
- Interventions
- Other: Placebo
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 101
- Registration Number
- NCT06514742
- Locations
- 🇭🇺
Bugat Pal Korhaz, Gyongyos, Hungary
🇺🇸UAB Huntsville Regional Medical Campus, Huntsville, Alabama, United States
🇺🇸IMA Clinical Research PC, Phoenix, Arizona, United States
A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
- Conditions
- Depressive Disorder, MajorAnhedonia
- Interventions
- Other: Placebo
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 444
- Registration Number
- NCT05550532
- Locations
- 🇦🇷
INSA Instituto de Neurociencias San Agustín, La Plata, Argentina
🇦🇷Clinica Privada de Salud Mental Santa Teresa de Ávila, La Plata, Argentina
🇦🇷C I A P Centro de investigacion y Asistencia en Psiquiatria, Rosario, Argentina
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 840
- Registration Number
- NCT05518149
- Locations
- 🇺🇸
University of Alabama at Birmingham - The Kirklin Clinic, Birmingham, Alabama, United States
🇺🇸SW Biomedical Research LLC, Tucson, Arizona, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
- Conditions
- Depressive Disorder, MajorAnhedonia
- Interventions
- Other: Placebo
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 513
- Registration Number
- NCT05455684
- Locations
- 🇨🇿
Narodni ustav dusevniho zdravi, Klecany, Czechia
🇨🇿Praglandia s r o, Prague 5, Czechia
🇨🇿Clintrial s r o, Praha 10, Czechia
A Study of 14C JNJ-67953964 in Healthy Adult Male Participants
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 8
- Registration Number
- NCT05197062
- Locations
- 🇳🇱
PRA Health Sciences, Groningen, Netherlands
A Study of JNJ-67953964 in Healthy Japanese Adult Male Participants
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2025-04-28
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 30
- Registration Number
- NCT04791332
- Locations
- 🇯🇵
Sumida Hospital, Tokyo, Japan
A Study to Investigate the Effect of JNJ-67953964 on Gastric Mucosal Integrity in Healthy Male and Female Participants
- First Posted Date
- 2019-12-04
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 76
- Registration Number
- NCT04185051
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression
- First Posted Date
- 2018-06-18
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 181
- Registration Number
- NCT03559192
- Locations
- 🇺🇸
Noble Clinical Research, Tucson, Arizona, United States
🇷🇺Psychoneurological dispensary 1, St-Petersburg, Russian Federation
🇺🇦Mnpe of Kharkiv Regional Council 'Regional Clinical Psychiatric Hospital #3', Kharkiv, Ukraine
Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?
- First Posted Date
- 2016-06-15
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- Yale University
- Target Recruit Count
- 17
- Registration Number
- NCT02800928
- Locations
- 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.